JAK 抑制剂：治疗坏疽性脓皮病的一种新型、安全且有效的疗法。
JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum.
机构信息
Oncoderma, São Paulo, Brazil.
Hospital Israelita Albert Einstein, São Paulo, Brazil.
出版信息
Int J Dermatol. 2023 Aug;62(8):1088-1093. doi: 10.1111/ijd.16676. Epub 2023 Apr 29.
BACKGROUND
Pyoderma gangrenosum currently lacks standardized therapy. New safer and more efficacious therapies are welcome.
AIMS
To present two new PG cases treated with JAK inhibitors, adding to the small existing experience METHODS & METHODS: Two case reports of PG patients successfully treated with tofacitinib and baricitinib.
RESULTS
Both patients were cured and presented no relapse. Patient # 1 used baricitinib 2 mg bid for 39 days while patient # 2 was treated with tofacitinib 5 mg bid for 120 days. No adverse reactions were seen.
DISCUSSION
The increasing usage of JAKi to treat inflammatory diseases had a positive reflex on PG therapy. Fifteen PG cases treated with these drugs had been found in literature and the two new cases here described add to the limited existing experience.
CONCLUSION
This is a novel use of tofacitinib and baricitinib beyond the approved indications. JAKi are a welcome addition to our options to manage patients with PG.
背景
坏疽性脓皮病目前缺乏标准化的治疗方法。欢迎更安全、更有效的新疗法。
目的
介绍两例使用 JAK 抑制剂治疗的 PG 新病例，增加目前有限的经验。
方法
两例 PG 患者成功接受托法替尼和巴瑞替尼治疗的病例报告。
结果
两名患者均治愈且无复发。患者 #1 使用巴瑞替尼 2 mg bid 治疗 39 天，而患者 #2 则使用托法替尼 5 mg bid 治疗 120 天。未观察到不良反应。
讨论
越来越多的 JAKi 被用于治疗炎症性疾病，这对 PG 的治疗产生了积极的影响。文献中发现了 15 例 PG 患者使用这些药物治疗，而这里描述的两个新病例增加了目前有限的经验。
结论
这是托法替尼和巴瑞替尼在批准适应证之外的新用途。JAKi 是我们治疗 PG 患者的可选方案之一，受到欢迎。
Zotero 插件